.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,048,035

« Back to Dashboard
Patent 8,048,035 protects EPIPEN and EPIPEN JR. and is included in one NDA. There have been zero Paragraph IV challenges on Epipen and Epipen Jr.

This patent has twenty-four patent family members in fifteen countries.

Summary for Patent: 8,048,035

Title:Automatic injector with needle cover
Abstract: An auto-injector automatically dispenses a predetermined dose of medicament upon activation. The auto-injector includes a needle cover operative to engage an injection site and activate the injector. The needle cover is configured to move from a locked retracted position prior to a medicament dispensing operation to a locked extended position after the medicament dispensing operation. The non-removable needle cover prevents contact with the needle both before and after the medicament dispensing operation.
Inventor(s): Mesa; C. Michael (Boyds, MD), Cors; Sarah Jane (Reston, VA), Penney; Melinda Fischer (Providence, RI), Tomellini; Dalita Rosemarie (Rehoboth, MA), Bremley; Mark Bumb (Edwardsville, IL), Wilmot; John Glyndwr (Mount Airy, MD), Young; Matthew Egerton (Over Cambs, GB), Raven; Sophie Rebecca (Swavesey Cambs, GB), Murphy; Martin Joseph (Letchworth Garden City Hearts, GB), Hurlstone; Christopher John (Newport Saffron Walden Essex, GB), Daintrey; Joseph William (Royston Herts, GB), Rochford; Craig Malcolm (Monxton Andover Hants, GB), Kirkwood; Stephen Philip (Haynes Beds, GB), Mathews; Colin James (Godmanchester Huntingdon, GB), Hill; Robert L. (Abingdon, MD)
Assignee: Meridian Medical Technologies, Inc. (Columbia, MD)
Application Number:12/258,754
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 49th percentile
Forward Citations: 9th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mylan Speclt
EPIPEN
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-001Dec 22, 1987RXYes8,048,035► subscribeY
Mylan Speclt
EPIPEN JR.
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-002Dec 22, 1987RXYes8,048,035► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,048,035

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,870,827Automatic injector► subscribe
7,449,012Automatic injector► subscribe
7,794,432Automatic injector with kickback attenuation► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,048,035

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4806712► subscribe
South Korea20070083539► subscribe
Mexico2007001298► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc